Get detailed information about the ProShares UltraShort Dow30 ETF. View the current DXD stock price chart, historical data, premarket price, dividend returns and more.
Please provide your email address to receive an email when new articles are posted on . Trastuzumab deruxtecan improved invasive DFS by 53% vs. T-DM1 for patients with residual disease after ...
BERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in different HER2-positive early-stage breast cancer settings in back-to-back ...
A Nigerian couple, Dr. Emmanuel Joseph and Grace Akpan, have warmed hearts online after tying the knot following 18 years of dating. The lovebirds, who met as teenagers in secondary school, exchanged ...
Shares of Sun Silver (ASX:SS1) jumped 22% to a record high after news broke of an upcoming briefing on the company’s Maverick Springs Project. This event takes place alongside upcoming Australia-US ...
Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...
Hosted on MSN
Koenigsegg Jesko SS1 First Look
Get an exclusive first look at the Koenigsegg Jesko SS1, showcasing the brand’s cutting-edge engineering and aerodynamic design. This review covers its extreme performance focus, advanced technology, ...
DXD Capital expects cautious optimism to replace the current prudence in the self storage lending environment, according to Bailey. Photo by Frankie Gomez Gallery, courtesy of DXD Capital Lending ...
Raludotatug deruxtecan (R-DXd) targets CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, offering a novel treatment option for patients with limited ...
R-DXd targets CDH6 in platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers, showing a 46% objective response rate in a phase 1 trial. FDA breakthrough therapy designation aims to ...
Ifinatamab deruxtecan targets B7-H3 and is a potential first-in-class antibody-drug conjugate for extensive-stage small cell lung cancer. The FDA's Breakthrough Therapy Designation aims to expedite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback